Arlington Heights
Northwest Community Healthcare - (Directions)
800 W Central Rd
Room 1-6 (Across from Auditorium)
Arlington Heights, IL
Meets: First Monday of each month, 7:00 - 9:00 PM
Contact Emily Nuzzo for more information.
Phone: 312.377.9030 x12
Email: Arlington Heights
Champaign-Urbana
Carl Forum - (Directions)
506 W. Park St.
Urbana, IL 61801
Meets: Second Wednesday of each month, 6:00 - 7:30 PM
Check Out The Champaign-Urbana Support Group's Newsletter:
Contact Penny Shonkwiler for more information.
Phone: 217.531.5371
Email: Champaign-Urbana
Chicago Support Group
God's House of Hope - (Directions)
231 E. 58th St.
Chicago, IL 60637-1301
Meets: 7:00 - 8:30 PM
Held on the Second Thursday of Each month, this support group offers Chicago and near-Chicago HCV patients an opportunity to share their experiences and learn from others.
Contact Rev. Gerald Hardy for more information.
Phone: 773. 493.8291 (312.377.9030)
Email: Chicago Support Group
Macon County:
Decatur
Macon County Health Department - (Directions)
1221 E. Condit
Decatur, IL 62521
Meets: Fourth Tuesday of each month, 6:30 - 7:30 PM
Contact Dianna Heyer, RN and Andrea Haubner, RN for more information.
Phone: 217.423.6988 x1320 (217.4236988 x1326)
Living with Hepatitis C
Loyola Medical Center, Outpatient Center - (Directions)
2160 S. 1st Avenue
Third Floor, Sub-Specialty Conference Room at Loyola Outpatient Center
Maywood, IL 60153
Meets: Thrid and Fourth Thursday of each month, 1:30-2:30 PM
Download the Group's Flyer
This support group will focus on psychosocial issues and stress management skills. It is intended for people coming with a diagnosis of Hepatitis C and for their family members.
Support groups provide people with a chance to share common experiences and to provide support for one another in working with stress, pain, illness, and the challenges and demands of everyday life.
The benefits vary person to person and may include:
A reduction in stress, learning more adaptive ways of coping with Hepatitis C, and improved quality of life.
Contact Loretta Murphy, BSN, RN; Susan Long, LCSW; Megan Merlock, Ph.D for more information.
Phone: 708.216.5454
New Beginnings-A support group for individuals living with liver disease
Fairfield, IA
Contact Robert Irno for more information.
Phone: 641-233-0105
PBCers
Contact Ivette Williams for more information.
Phone: 773.779.7602
Email: PBCers
Peer to Peer Support Network
Click Here To Visit The Peer To Peer Support Group Website
Contact Emily Nuzzo for more information.
Phone: 312.377.9030 x12
Email: Peer to Peer Support Network
PSC
For additional resources:
www.pscpartners.org
www.psc-support.com
www.psc-literature.org
Contact Becky Long for more information.
Phone: 773-255-0428
Email: PSC
Quad Cities
First Evangelical Lutheran Church - (Directions)
5th Ave. and 13th St
Moline, IL
Meets: Third Tuesday of each month, 6:30 - 8:00 PM
Upcoming Quad Cities Support Group Meetings:
Tuesday, February 19, 2008 at 6:30 PM
Tuesday, March 18, 2008 at 6:30 PM (Quad Cities Support Group and St. Patrick's Day Celebration)
Tuesday, April 15, 2008 at 6:30 PM
Tuesday, May 20, 2008 at 6:30 PM
Contact William Bahnks for more information.
Phone: 1-309-762-8193
Rockford
Odd Months: Harlem United Methodist Church/Even Months: Brooke Road United Methodist Church - (Directions)
Odd Months: 8401 North Alpine Road
Even Months: 1404 Brooke Road
Rockford, IL
Meets: Third Thursday of each month, 6:45 - 9:00 PM
Contact Brenda Erwin for more information.
Phone: 815.391.5100
Springfield-"Sangamon Area Hepatitis Support Group"
Springfield Department of Public Health - (Directions)
1415 East Jefferson
Main Floor Conf. Room
Springfield, IL
Meets: Third Monday of each month, 6:00 - 8:00 PM
Contact Don Hunt for more information.
Phone: 217.789.2182
Email: Springfield-"Sangamon Area Hepatitis Support Group"
Winfield (formerly Naperville & Geneva)
Central DuPage Hospital
25 N. Winfield Rd
Meets: First Thursday of each month, 7:00 - 8:30 PM
Thursday, May 1, 2008
Special Topic Presentation:
Liver Health: Overcoming Secret Enemies In Our Environment
Click Here For More Information
Contact Kelly Hofmann for more information.
Phone: 630.399.5709
Email: Winfield (formerly Naperville & Geneva)
Acute Liver Failure - Northwestern University
Multi Center Group to Study Acute Liver Failure (ALF), Long-term Outcomes of ALF Patients
To prospectively obtain tissue and blood samples from patients with ALF and encephalopathy. The present study will allow an in-depth analysis of cases of acute liver failure and 40 centers around the United States in the ALF Study Group (ALFSG), with an emphasis on the cause and treatment of this condition.
Contact Jeanne Gottstein for more information.
Phone: 312.908.5902
Acute Liver Failure - Northwestern University
The Impact of Preoperative Overt Hepatic Encephalopathy on Neurological Recovery After Liver Transplantation
Comparison of cognitive dysfunction in liver transplant recipients with and without a history of overt hepatic encephalopathy prior to transplantation.
Cmparison of cognitive dysfunction in liver transplant recipients with a history of hepatic encephalopathy prior to transplantation accordidng to liver disease severity as measured by Model for End-stage Liver Disease (MELD) score.
Contact Jeanne Gottstein for more information.
Phone: 312.908.5902
Acute Liver Failure - Northwestern University
Pilot Trial on the Effect of Mild Hypothermia on Intracranial Pressure in Patients with Acute Liver Failure (ALF)
A randomized controlled trial of mild hypothermia (33 degrees C) and Standard Medical Treatment (SMT) vs. SMT alone in patients with Acetaminophen-induced (APAP-induced) ALF who have developed severe encephalopathy (stupor and/or coma).
Contact Jeanne Gottstein for more information.
Phone: 312.908.5902
Acute Liver Failure - Northwestern University
The Early Use of Sanvar with Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension
To determine the efficacy of the early administration of Sanvar (vapreotide) in association with endoscopic treatment for the control of bleeding at 5 days, i.e. control of initial bleeding and prevention of early re-bleeding, plus survival.
Contact Jeanne Gottstein for more information.
Phone: 312.908.5902
Hepatitis B - Northwestern University
A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtrictabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects with Decmpensated Liver Disease and in the Prevention of Hepatitis B Recurrence Post-Transplantation
To compare Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatement of Chronic Hepatitis B Subjects with Decompensated liver disease. Please call for inclusion criteria.
Contact Kim Sipich for more information.
Phone: 312.503.0121
Hepatitis B - Northwestern University
Prospective, Randomized, Trial to Investigate the Effect of Continued Adefovir Versus Combination Regimens of Telbivudine plus Adefovir, and Telbivudine plus Tenofovir in patients with Chronic Hepatitis B and Suboptimal Viral Suppression (PROACTIV study)
To investigate the effect of continued Adefovir versus combination regimens of Telbivudine plus Adefovir, and Telebivudine plus Tenofovir in Patients with Chronic Hepatitis B and suboptimal viral suppression.
Contact Kim Sipich for more information.
Phone: 312.503.0121
Hepatitis B - Rush University
HBV-Comparing Tenofovir, Truvada and Entecavir
- CPT>7
- HBV DNA greater than or equal to 10(3) copies/ml
- HBsAg for at least 6 months positive serum
- Negative HIV, HCV, HDV serologies
- Less than 24 months of total prior adefovir dipivoxil exposure
- Decompensated liver function with cirrhosis
- Serum ALG 10 x ULN
- Randomized to Tenofovir vs Truvada vs Entecavir
Contact Monique Williams for more information.
Phone: 312.563.3919
Hepatitis B - Rush University
HBV - Assessing Entecavir
- African American and Hispanic Chronic HBV nucleoside/tide-Naive
- Chronic HBV, either HBeAg-positive (HBeAb-negative) or HBeAg-Negative (HBeAb-positive) disease
- HBV DNA > 10(4) copies/ml
- Compensated liver function
- ALT of 1.3 to 10 x ULN
Contact Monique Williams for more information.
Phone: 312.563.3919
Hepatitis B - Rush University
HBV-Comparing Adefovir, Telbivudine and Adefovir, Tenofovir & Telbivudine
- Suboptimal resonse to Adefovir: >5 months on Adefovir
- Normal ALT up to 10 x ULN
- >1,000 copies/ml
- Cirrhosis vs. non-cirrhosis
- Randomized to Adefovir vs Telbivudine & Adfovir vs. Tenofovir & Telbivudine
Contact Monique Williams for more information.
Phone: 312.563.3919
Hepatitis B - University of Chicago
A study to describe the antiviral effect of Entecavir (ETV) in Blacks/African-Americans and Hispanics with Chronic HBV infection who are nucleoside/tide-naive. Inclusion criteria: age 18 years and older, HBe antigen positive or negative, nucleoside/tide-naive, ALT 1.3 to 10 x ULN. Exclusion criteria: history of decompensated cirrhosis, co-infection with HCV, HIV, or HDV, alcohol or drug abuse within the last 12 months.
Contact Katie Wherity, RN BSN for more information.
Phone: 773.702.4477
Hepatitis C (Partial Responders to Previous Treatment) - University of Chicago
A Phase 2 study of a HCV polymerase inhibitor prodrug in combination with Pegylated Interferon and ribavirin for HCV treatment naive patients. Inclusion criteria: Age 18-65 years, HCV genotype 1, HCV RNA level greater than or equal to 50,000 IU/mL and liver biopsy within the past 2 years. Exclusion criteria: Previous HCV treatment, cirrhosis, decompensated liver disease, alcohol or drug abuse within last 12 months.
Contact Katie Wherity, RN BSN for more information.
Phone: 773.702.4477
Hepatitis C (Treatment naïve) - University of Chicago
A Phase 2 study comparing weight based doses of viramidine combined with Pegasys and ribavirin versus Pegasys plus ribavirin in treatment naive, genotype 1 HCV patients. Inclusion criteria: >18 years old, genotype 1, HCV RNA level > 2,000 copies, biopsy within the last 3 years. Exclusion criteria: cirrhosis, weight .128kg or < 40kg, no methadone, no substance abuse within the last year.
Contact Katie Wherity, RN BSN for more information.
Phone: 773.702.4477
Hepatitis C (Treatment naïve) - University of Chicago
A Phase 4 study of high dose induction of Pegylated Interferon with Ribavirin for patients with Hepatitis C who have never been treated before. Inclusion critera: Age 18 years and older, HCV, Genotype 1, weight > 85kg, liver biopsy within the past two years. Exclusion critera: Previous HCV treatment, decompensated liver disease, alcohol or drug abuse within last 12 months.
Contact Katie Wherity, RN BSN for more information.
Phone: 773.702.4477
Hepatitis C (Treatment naïve) - University of Chicago
A Phase 3, randomized study to evaluate albumin interferon in combination with ribavirin as compared to Pegasys plus ribavirin therapy for gentype 2 or 3 treatment naive patients. Inclusion criteria: >18 years old, biopsy within 2 years of enrollment, genotype 2 or 3. Exclusion criteria: no decompnsated liver disease, no substance abuse within the last 6 months, platelet count < 90,000.
Contact Katie Wherity, RN BSN for more information.
Phone: 773.702.4477
Hepatitis C - Northwestern University
A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b in Combination with Ribavirin Compared with Peginterferon Alfa-2a in Combination with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 1
To evaluate the safety and efficacy of alb-IFN given with Ribavirin compared to IFN-alfa 21/2b plus ribavirin (the standard of care). Please contact University for inclusion criteria
Contact Kim Sipich for more information.
Phone: 312.503.0121
Hepatitis C - Northwestern University
Comparison of Weight-based Doses of Taribavirin Combined with Peginterferon Alfa-2b Versus Ribavirin Combined with Peginterferon Alfa-2b in Therapy-naive Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
To evaluate the safety and efficacy of Taribavirin when given with IFN-alfa 2b vs. Ribavirin given with IFN-alfa 2b (the standard of care). Please contact the University for inclusion criteria.
Contact Kim Sipich for more information.
Phone: 312.503.0121
Hepatitis C - Rush University
HCV - Higher doses of Pegasys/Peg-Interferon and Riba
- Weight of 187 lbs or more
- Naive
- Genotype 1
- Confirmed HCV antibody test
- HCV RNA greater than or equal to 400,000
Contact Monique Williams for more information.
Phone: 312.563.3919
Hepatitis C - Rush University
HCV - Comparing Pegylated Interferon vs. Infergen
- Currently on Pegasys/Peg-Intron for less than 12 weeks
- Genotype 1
- Had 2 log drop? If so, you could randomized to Pegylated Interferon vs. Infergen
- Liver biopsy within last 24 months
Contact Monque Williams for more information.
Phone: 312.563.3919
Hepatitis C - University of Illinois at Chicago
A Phase IIb Clinical Trial to Evaluate the Combination of Pegylated Interferon Alfa plus Valopicitabine (NM283) in Treatment-Naïve Patients with Chronic Hepatitis C
Available for treatment-naïve patients with Hepatitis C. The purpose of this study is to evaluate the safety and viral activity of the protease inhibitor NM283 with peg-interferon alfa-2a in genotype 1a or 1b-infected patients who have a baseline viral load of at least 500,000. No liver biopsy will be required. The patients will be randomized to one of 4 treatment arms which all include NM283 and IFN. Patients will receive at least 24 weeks of treatment. If the patient demonstrates < 250,000 RNA at week 24 they will continue on study drug for up to week 48.
Contact Rebecca Duke, NP for more information.
Phone: 312.996.8907
Hepatitis C - University of Illinois at Chicago
Interferon Resistance in Genotype 1 Infected Patients
Available for genotype 1-infected patients who have never been treated for Hepatitis C. The purpose of this study is to assess viral kinetics in patients receiving the standard treatment with peg-interferon alfa-2a and ribavirin. The study is available for African-American, Hispanic and Caucasian patients only. The study involves frequent blood draws and one overnight stay in the GCRC in the hospital.
Contact Rebecca Duke, NP for more information.
Phone: 312.996.8907
Hepatitis C - University of Illinois at Chicago
Phase 2 Randomized, Dose-Ranging, Open-label Study of the Safety and Tolerability of Consensus Interferon-Alpha (CIFN) plus Interferon Gamma-1b with or without Ribavirin in the Treatment of Patients with Chronic Hepatitis C who are non-responders to PEG-IFN-a plus RBV (Closed for enrollment and will reopen soon).
Available for patients (all genotypes) who have not responded to pegylated interferon (Peg-Intron or Pegasys) and ribaiin. Patients will be randomized into cohorts with differing doses of daily CIFN, thrice weekly IFN-gamma 1b, and daily ribavirin. If there is a > or equal to 21og drop in viral load at week 24, the patient will be continued on the treatment regimen until week 48
Contact Rebecca Duke, NP for more information.
Phone: 312.996.8907
Hepatitis C/Pre-Liver Transplantation - University of Illinois at Chicago
Hepatitis C Virus Kinetics after Liver Transplantation: Impact of Living Donor Liver Transplantation and Pre-Transplant Antiviral Therapy
Available for patients waiting for liver transplantation with the primary liver disease of Hepatitis C. Patients will be placed in 3 groups: cadaveric liver transplantation, living donor liver transplantation, or living donor transplantation who will receive “standard” treatment for HCV with pegylated interferon and ribavirin for 12 weeks before the transplant operation. The study involves frequent blood draws one day before the operation, during the operation and up to 8 weeks post-op.
Contact Rebecca Duke, NP for more information.
Phone: 312.996.8907
Hepatocellular Carcinoma (HCC) - University of Chicago
A national registry of patients with hepatocellular carcinoma, which will evaluate the etiologic factors associated with HCC and to survey and stage the potential treatability of patients with HCC.
Contact Katie Wherity, RN BSN for more information.
Phone: 773.702.4477
Hepatocellular Carcinoma (HCC) - University of Chicago Hospitals
A national registry of patients with hepatocellular carcinoma, which will evaluate the etiologic factors associated with HCC and to survey and stage the potential treat ability of patients with HCC.
Contact Katie Wherity, RN, BSN for more information.
Phone: 773.702.4477
Hepatocellular Carcinoma (HCC) - University of Illinois at Chicago
Study of DENSPM in Patients with Hepatocellular Carcinoma
Study of new chemotherapeutic agent, DENSPM, in patients with hepatocellular carcinoma. Available for patients with unresectable (cannot be surgically removed) liver tumors and who are not eligible for chemoemolization. Patients will receive infusions of DENSPM to reduce the size or stop the growth of liver tumors.
Contact Rebecca Duke, RN for more information.
Phone: 312.996.8907
Liver Transplantation - Northwestern University
Adult to Adult Living Donor Liver Transplant Cohort Study
The purpose of this study is to provide valuable information on the outcomes of adult to adult living donor liver transplantation (AALDLT). This information is gathered in order to aid decisions made by physicians, patients, and potential donors. This cohort study involves nine geographically distributed transplant centers and continues through 2009. Inclusion trial criteria: Adult (18 or older), be a liver donor or portential recipient of a living related donor liver.
Contact Patrice Al-Saden, RN for more information.
Phone: 312.503.1058
Liver Transplantation - Northwestern University
Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C after Living Donor Liver Transplantation
The purpose of this study is to learn if pre-liver transplant treatment, using peginterferon plus ribavirin, will clear HCV RNA from the blood in HCV-infected recipients and reduce the risk of recurrent HCV and re-infection of the new liver with hepatitis following liver transplant. Patients awaiting deceased donor liver transplant will be asked to enroll in the protocol at the time of identification of a potential living liver donor. This study involves about nine centers int he US and will be enrolling 150 patients over a four-year period. Inclusion trial criteria: Adult (18 years of age or older), LDLT candidate, HCV RNA positive, expected time on treatment is at least 12 weeks.
Contact Patrice Al-Saden, RN for more information.
Phone: 312.503.1058
Liver Transplantation - Northwestern University
A Prospective, Open-label, Multi-center, Randomized Trial of the Efficacy and Safety of a Long Term Calcineurin Inhibitor Free Maintenance Regimen with Mycophenolate Mofetil and Siroliumus in Recipients of an Orthotopic Liver Transplant.
The purpose of this study is to evaluate Mycophenolate Mofetil (MMF) + Sirolimus as CNI-free regimen at 12 months post transplant: for preservation of renal function in recipients of an orthotopic liver transplant and for prevention of biopsy-proven acute rejection, graft loss, death, or loss to follow-up. Inclusion trial criteria: male or female patients betwen 18 and 74 years, patients who have received a singly primary liver transplant, patients who have been on MMF plus Tacrolimus or Cyclosporine from the time of transplant (within 72 hours), hepatitis C positive patients who have had an intraoperative (back table) biopsy of the transplanted liver or will have a biopsy at the time of randomization, female patients with negative serum pregnancy test within 7 days prior to randomization.
Contact Linda B. Roberts, RN for more information.
Phone: 312.503.0252
Liver Transplantation - Northwestern University
Adult to Adult Living Donor LiverTransplant Cohort Retrospective Study.
This study hopes to identify the genes involved in the development of liver cancer in patients with Hepatitis C cirrhosis. In addition, examination of the genes implicated in tumor progression in patients with Hepatitis C/liver cancer while waiting for transplantation. Determine the potential role of the genetic markers in predicting post-transplantation outcomes in Hepatitis C infected patients with liver cancer. Inclusion trial criteria: all patients with a diagnosis of hepatocellular carcinoma from August 1, 1994 through October 31, 2005.
Contact Patrice Al-Saden, RN for more information.
Phone: 312.503.1058
LiverTransplantation - Northwestern University
Adult-to-Adult Living Donor Liver Transplant Cohort Study - Genomics and Regeneration in the Transplant Setting GRITS Protocol
To determine and validate the molecular signatures of graft injury and recovery processes within regenerating living donor liver grafts compared to deceased donor grafts. Also to determine the impact of donor and recipient clinical variables on successful initiation and progression of regenerative and metabolic molecular pathways in the allograft. Inclusion trial criteria: This study population will include patients with end-stage liver disease who meet the standard criteria for liver transplantation from a cadaveric or living donor, as well as living donors, enrolled in the A2ALL study and consent to this ancillary study. Subjects will include all potential liver transplant recipients and living donors at the participating A2ALL transplant centers who are 18-80 and will not be excluded based upon gender or economic status. The patient must be evaluated by members of the transplant team and complete the multidisciplinary evaluation prior to being approved for donation. Potential donors must undergo the laboratory and radiologic evaluation that is required by the transplant center and be approved by the Transplant Center Selection Committee.
Contact Patrice Al-Saden, RN for more information.
Phone: 312.503.1058
LiverTransplantation - Northwestern University
Adult-to-Adult Living Donor Liver Transplant Cohort Study - Genomics and Regeneration in the Transplant Setting GRITS Protocol
To determine and validate the molecular signatures of graft injury and recovery processes within regenerating living donor liver grafts compared to deceased donor grafts. Also to determine the impact of donor and recipient clinical variables on successful initiation and progression of regenerative and metabolic molecular pathways in the allograft. Inclusion trial criteria: This study population will include patients with end-stage liver disease who meet the standard criteria for liver transplantation from a cadaveric or living donor, as well as living donors, enrolled in the A2ALL study and consent to this ancillary study. Subjects will include all potential liver transplant recipients and living donors at the participating A2ALL transplant centers who are 18-80 and will not be excluded based upon gender or economic status. The patient must be evaluated by members of the transplant team and complete the multidisciplinary evaluation prior to being approved for donation. Potential donors must undergo the laboratory and radiologic evaluation that is required by the transplant center and be approved by the Transplant Center Selection Committee.
Contact Patrice Al-Saden, RN for more information.
Phone: 312.503.1058
LiverTransplantation - Northwestern University
Adult-to-Adult Living Donor Liver Transplant Cohort Study - Genomics and Regeneration in the Transplant Setting GRITS Protocol
To determine and validate the molecular signatures of graft injury and recovery processes within regenerating living donor liver grafts compared to deceased donor grafts. Also to determine the impact of donor and recipient clinical variables on successful initiation and progression of regenerative and metabolic molecular pathways in the allograft. Inclusion trial criteria: This study population will include patients with end-stage liver disease who meet the standard criteria for liver transplantation from a cadaveric or living donor, as well as living donors, enrolled in the A2ALL study and consent to this ancillary study. Subjects will include all potential liver transplant recipients and living donors at the participating A2ALL transplant centers who are 18-80 and will not be excluded based upon gender or economic status. The patient must be evaluated by members of the transplant team and complete the multidisciplinary evaluation prior to being approved for donation. Potential donors must undergo the laboratory and radiologic evaluation that is required by the transplant center and be approved by the Transplant Center Selection Committee.
Contact Patrice Al-Saden, RN for more information.
Phone: 312.503.1058
NASH (nonalcoholic steatohepatitis) - Northwestern University
A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH with Xenical Followed by Treatment of Hepatitis C (HCV) with PEG-Interferon alpha-2a/Copegus
The primary objective of this study is to compare the efficacy of PEG-Interferon alfa-2a (Pegasys) and Ribavirin (Copegus) for 24 or 48 weeks (depending on HCV genotype) in a group of naive,overweight (BMI >27 kg/m2), HCV positive patients with histologic NASH or significant hepatic steatosis, who were either previoulsy treated witn Xenical or placebo for 36 weeks.
Contact Jessica Zagory for more information.
Phone: 312.503.0623
NASH (nonalcoholic steatohepatitis) - Northwestern University
The Effect of Pentoxifylline on Nonalcoholic Steatohepatitis (NASH)
An investigational study exploring the potential benefit of pentoxifylline for the treatment of NASH. Effectiveness will be determined by taking blood samples and a liver biopsy. Two thirds of the patients will receive pentoxifylline and one-third will receive a placebo (sugar pill). Subjects will also be encouraged to achieve modest weight loss via low fat diet and exercise. Pentoxifylline has been safely used for the treatment of alcohol related liver disease and poor circulation, and is currently not approved for NASH. Pentoxifylline is a pill which is taken three times a day.
Contact Jeanne Gottstein for more information.
Phone: 312.908.6192
NASH (nonalcoholic steatohepatitis) - Northwestern University
The Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients
The purpose of this study is to examine variability of hepatic histology as well as expression of key metabolic genes in NAFLD/NASH patients undergoing bariatric surgery. Patients will undergo pre-operative laboratory testing, followed by intra-operative liver and fat biopsies. A 12-month follow up will consist of repeat liber biopsy and laboratory testing.
Contact Jessica Zagory for more information.
Phone: 312.503.0623
NASH (nonalcoholic steatohepatitis) - Northwestern University
The Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients
The purpose of this study is to examine variability of hepatic histology as well as expression of key metabolic genes in NAFLD/NASH patients undergoing bariatric surgery. Patients will undergo pre-operative laboratory testing, followed by intra-operative liver and fat biopsies. A 12-month follow up will consist of repeat liber biopsy and laboratory testing.
Contact Jessica Zagory for more information.
Phone: 312.503.0623
NASH (nonalcoholic steatohepatitis) - Northwestern University
The Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients
The purpose of this study is to examine variability of hepatic histology as well as expression of key metabolic genes in NAFLD/NASH patients undergoing bariatric surgery. Patients will undergo pre-operative laboratory testing, followed by intra-operative liver and fat biopsies. A 12-month follow up will consist of repeat liber biopsy and laboratory testing.
Contact Jessica Zagory for more information.
Phone: 312.503.0623
NASH (nonalcoholic steatohepatitis) - University of Illinois at Chicago
A Pilot Study to Evaluate the Effect of Combination Therapy of Omega-3 Fatty Acids and Vitamin E on Hepatic Steatosis and Factors Associated with Steatohepatitis
Available for patients with liver biopsy-proven NASH (nonalcoholic steatohepatitis). Patients will receive an MRI scan before treatment starts to measure the amount of fat in and around the liver. Patients will meet with a dietitian regarding gradual weight loss and will be randomized into two groups – one receiving omega-3 fatty acids (fish oil) and vitamin E – and one receiving no omega-3 fatty acid supplementation. Another MRI scan will be performed on all patients at the end of the study. Patients will receive treatment for 24 weeks. There is no standard-of-care treatment for fatty liver and the effect of supplementation with omega-3 fatty acids combined with vitamin E needs to be studied.
Contact Rebecca Duke for more information.
Phone: 312.996.8907
NASH (nonalcoholic steatohepatitis) - University of Illinois at Chicago
A Pilot Study of the Interaction Among Sleep Apnea, Nonalcoholic Fatty Liver Disease and Oxidative Stress
Available for patients with liver biopsy-proven diagnosis of NASH (nonalcoholic steatohepatitis) and a BMI (body mass index) of >30. Patients will be admitted to the General Clinical Research Center (GCRC) for an overnight sleep study with blood tests to evaluate whether they have sleep apnea and to track changes in liver enzymes overnight. If a patient does have sleep apnea, they will be asked to return for another overnight sleep study using a CPAP machine to control the apnea and for blood tests to evaluate if liver enzymes improve with treatment for the sleep apnea. This study will evaluate whether NASH, combined with sleep apnea increases oxidative stress and consequently increases liver damage.
Contact Rebecca Duke for more information.
Phone: 312.996.8907
Print
del.icio.us